Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection.

Susanna Vuorenoja, Kim Vettenranta, Olli Lohi

Open access · goldAbstract readCase Reports

In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.5field-weighted citation impact, top 34% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection.Cancer reports (Hoboken, N.J.) · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Susanna VuorenojaTampere Center for Child, Adolescent and Maternal Health Research, Tays Cancer Centre, Tampere University Hospital, Tampere University, Tampere, Finland.ORCID 0000-0003-3816-0678

Kim VettenrantaPediatric Research Center, University of Helsinki, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.

Olli LohiTampere Center for Child, Adolescent and Maternal Health Research, Tays Cancer Centre, Tampere University Hospital, Tampere University, Tampere, Finland.

Tampere University Hospital · FIUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic myeloid leukemia (CML) is a rare disease in children and treated with tyrosine kinase inhibitors (TKI) and with allogeneic hematopoietic stem cell transplantation (HSCT) still in many cases. CASE: We describe an 8-year-old patient with CML treated with two different TKIs before proceeding to allogeneic HSCT. Despite successful engraftment, prompt rejection of the graft was followed by autologous reconstitution. TKI therapy was reintroduced post-rejection in anticipation of relapse but shortly discontinued due to low white blood cell and neutrophil counts. The patient has remained disease-free over 5 years after graft rejection and without further therapy.

conclusionThis case suggests that even a short antileukemic effect by an allogeneic transplant may succeed in eradicating CML.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAllograftsChildHumansProtein Kinase InhibitorsTransplantation, HomologousProtein Kinase InhibitorsCMLeradicationgraft rejectionHSCTreconstitution

Identifiers

PMID35796282

DOI10.1002/cnr2.1663

PMCPMC9575499

OpenAlexW4284693930

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.